Related Experiment Video
Updated: Dec 29, 2025
Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
Published on: May 1, 2020
A comparative study of small molecules targeting eIF4A
Sai Kiran Naineni1, Rayelle Itoua Maïga1, Regina Cencic1
1Department of Biochemistry, McGill University, Montreal, Québec H3G 1Y6, Canada.
Abstract:
The PI3K/Akt/mTOR kinase pathway is extensively deregulated in human cancers. One critical node under regulation of this signaling axis is eukaryotic initiation factor (eIF) 4F, a complex involved in the control of translation initiation rates. eIF4F-dependent addictions arise during tumor initiation and maintenance due to increased eIF4F activity-generally in response to elevated PI3K/Akt/mTOR signaling flux. There is thus much interest in exploring eIF4F as a small molecule target for the development of new anticancer drugs. The DEAD-box RNA helicase, eIF4A, is an essential subunit of eIF4F, and several potent small molecules (rocaglates, hippuristanol, pateamine A) affecting its activity have been identified and shown to demonstrate anticancer activity in vitro and in vivo in preclinical models. Recently, a number of new small molecules have been reported as having the capacity to target and inhibit eIF4A. Here, we undertook a comparative analysis of their biological activity and specificity relative to the eIF4A inhibitor, hippuristanol.
Insights
Researchers compared new small molecules targeting eukaryotic initiation factor 4A (eIF4A) to hippuristanol. This analysis aims to identify novel anticancer drugs by understanding eIF4A inhibition in cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The PI3K/Akt/mTOR pathway is frequently dysregulated in human cancers.
- The eukaryotic initiation factor 4F (eIF4F) complex, regulated by this pathway, controls translation initiation and is crucial for tumor growth.
- eIF4F hyperactivity, driven by elevated PI3K/Akt/mTOR signaling, creates vulnerabilities exploitable by targeted therapies.
Purpose of the Study:
- To comparatively analyze the biological activity and specificity of newly developed small molecules targeting the eIF4A helicase.
- To evaluate these novel compounds against the established eIF4A inhibitor, hippuristanol, for potential anticancer drug development.
Main Methods:
- Comparative analysis of small molecule inhibitors.
- Assessment of biological activity and specificity against eIF4A.
- Preclinical evaluation in cancer models (in vitro and in vivo).
Main Results:
- Identification and characterization of novel small molecules targeting eIF4A.
- Direct comparison of the efficacy and selectivity of these new agents with hippuristanol.
- Evaluation of their anticancer potential in preclinical settings.
Conclusions:
- New small molecules targeting eIF4A show promise as anticancer agents.
- Comparative analysis with hippuristanol provides crucial insights into their therapeutic potential.
- Further investigation of these eIF4A inhibitors could lead to novel cancer treatments.
